L-(+)-Arabinose

Research use only, not for human use.

L-(+)-Arabinose inhibits intestinal sucrase activity, thereby reducing sucrose utilization, and consequently decreasing lipogenesis.

L-(+)-Arabinose inhibits intestinal sucrase activity, thereby reducing sucrose utilization, and consequently decreasing lipogenesis.(In Vitro):L-(+)-Arabinose is found to be associated with ribose-5-phosphate isomerase deficiency, which is an inborn error of metabolism.L-(+)-Arabinose selectively inhibits intestinal sucrase activity in a noncompetitive manner and suppresses the plasma glucose increase due to sucrose ingestion. (In Vivo):L-(+)-Arabinose feeding reduced the weights of epididymal adipose tissue in rats. Moreover, plasma insulin and triacylglycerol concentrations were significantly reduced by dietary L-(+)-Arabinose. L-(+)-Arabinose suppresses gluconeogenesis through modulating AMP-activated protein kinase in metabolic disorder mice.

L-(+)-Arabinose selectively inhibits intestinal sucrase activity in a noncompetitive manner and suppresses the plasma glucose increase due to sucrose ingestion. L-(+)-Arabinose is found to be associated with ribose-5-phosphate isomerase deficiency, which is an inborn error of metabolism.

——

——

Proteasome/Ubiquitin

Endogenous Metabolite

Interleukin

——

——

5328-37-0

150.13

C5H10O5

>98% (HPLC)

In Vitro:?H2O : 500 mg/mL (3330.45 mM)

OC[C@H](O)[C@H](O)[C@@H](O)C=O

——

(-20℃)

With Ice Pack

≥ 2 years